Article Text

Download PDFPDF
Combination treatment of intravenous immunoglobulin and cultivated oral mucosal epithelial transplantation for ocular cicatricial pemphigoid
  1. Y Uchino1,
  2. S Takahashi1,
  3. M Uchino2,
  4. J Shimazaki3
  1. 1Department of Dermatology, Tokyo Dental College, Chiba, Japan
  2. 2Department of Ophthalmology, Keio University, Tokyo, Japan
  3. 3Department of Ophthalmology, Tokyo Dental College, Chiba, Japan
  1. Correspondence to: Dr Y Uchino Department of Ophthalmology, Tokyo Dental College, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan; uchino{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Ocular cicatricial pemphigoid (OCP) is a progressive cicatrising autoimmune disease affecting the skin and mucous membranes, including ocular surface epithelia.1 Although systemic immunosuppression is advocated, both progression of ocular surface inflammation and systemic side effects remain a problem.2 Intravenous administration of immunoglobulin (IVIg) is an immunomodulating treatment, and encouraging results have been reported for acute-phase OCP.3 However, corneal scarring and neovascularisation have also been reported. Cultivated oral mucosal epithelial transplantation (COMET) is a recently developed surgical method for ocular surface transplantation.4 Autologous oral epithelial cells were cultivated on preserved amniotic membranes, and the sheets were transplanted after fibrotic tissue excision. As autologous cells are used, immunological rejection is avoided, thereby eliminating complications associated …

View Full Text


  • Competing interests: None.